Re-analysis Questions Bremelanotide's Clinical Benefit for Low Sexual Desire in Women

Hypoactive Sexual Desire Disorder (HSDD) is characterized by a persistent or recurrent deficiency or absence of sexual fantasies and desire for sexual activity, causing significant distress. Bremelanotide, marketed as Vyleesi, was approved to treat premenopausal women with acquired, generalized HSDD. However, there has been ongoing debate regarding the true clinical efficacy and significance of its original Phase III trial results, leading to a need for independent scrutiny of the reported benefits.

The re-analysis revealed that while bremelanotide did show a statistically significant increase in satisfying sexual events (SSEs) compared to placebo, the magnitude of this effect was notably small. The mean increase in SSEs per month was 0.5 to 0.6 for the bremelanotide group, compared to 0.3 to 0.4 for the placebo group, resulting in a net difference of only 0.2 to 0.3 additional SSEs per month. Furthermore, the study found no statistically significant difference between bremelanotide and placebo in reducing personal distress associated with low sexual desire, a critical component of the HSDD diagnosis. These findings suggest that the drug's impact on core HSDD symptoms was marginal at best. The re-analysis concluded that the observed increase in satisfying sexual events with bremelanotide was of minimal clinical significance, with effect sizes considered small and unlikely to translate into a meaningful real-world benefit for most women.